GlassScriptPhysician profile
Jami M Devarona
NPI 1356415491
$11,020.80
in general payments reported to CMS, 2019-2025
44 companies · $2,060 in 2025
The $2,060 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,489 · 2022: $2,541 · 2023: $2,684 · 2024: $2,247 · 2025: $2,060.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,991.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,991.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,989.27 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,826.99 | 2021-2025 | |
| Lilly USA, LLC | $904.71 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $849.11 | 2021-2025 | |
| Amgen INC. | $717.72 | 2021-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $603.01 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $570.48 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $406.01 | 2021-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $323.71 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $234.16 | 2022-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $229.33 | 2022-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Otsuka America Pharmaceutical, INC. | $213.85 | 2023-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $212.33 | 2021-2025 | Spravato |
| Axsome Therapeutics, INC. | $158.43 | 2025 | Auvelity |
| Novartis Pharmaceuticals Corporation | $148.53 | 2022-2025 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $142.68 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Dexcom, INC. | $104.26 | 2021-2023 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $103.02 | 2022 | |
| Sanofi Pasteur INC. | $99.57 | 2021-2024 | |
| Radius Health, INC. | $97.68 | 2022-2025 | Tymlos |
| Averitas Pharma INC. | $97.47 | 2023-2024 | Qutenza |
| Kowa Pharmaceuticals America, INC. | $92.14 | 2022-2025 | Livalo, Seglentis, Zoryve |
| Biohaven Pharmaceuticals, INC. | $86.69 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $85.00 | 2021-2024 | Austedo Xr, Airduo Digihaler |
| Halozyme INC | $84.10 | 2023 | |
| Amarin Pharma, INC. | $83.58 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $78.47 | 2021-2025 | Eliquis |
| Sanofi-Aventis U.S. LLC | $63.58 | 2021-2022 | |
| Inspire Medical Systems, INC. | $47.12 | 2023 | Inspire |
| Viatris Specialty LLC | $46.48 | 2025 | Yupelri |
| Astellas Pharma US INC | $33.70 | 2022-2024 | Veozah |
| Mylan Specialty L.P. | $33.59 | 2024 | Yupelri |
| Eisai INC. | $33.20 | 2025 | |
| Baxter Healthcare | $30.72 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Phathom Pharmaceuticals, INC. | $29.35 | 2024 | Voquezna |
| Grt US Holding, INC. | $29.14 | 2022 | |
| Antares Pharma, INC. | $19.90 | 2024 | Xyosted |
| Paratek Pharmaceuticals, INC. | $18.91 | 2022 | |
| Neurocrine Biosciences, INC. | $18.83 | 2025 | |
| Verity Pharmaceuticals INC. | $16.79 | 2025 | Tlando |
| Vertex Pharmaceuticals Incorporated | $14.56 | 2025 | |
| Phadia US INC. | $14.29 | 2025 | Immunocap |
| Idorsia Pharmaceuticals US INC | $14.28 | 2024 | Quviviq |
| Tolmar, INC. | $14.06 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jami Devarona listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.